
Choksi Laboratories Ltd is Rated Strong Sell
2026-03-16 10:10:47Choksi Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 February 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 16 March 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Choksi Laboratories Ltd Falls to 52-Week Low Amidst Continued Downtrend
2026-03-04 12:44:53Choksi Laboratories Ltd, a player in the Healthcare Services sector, has touched a new 52-week low of Rs.81.85 today, marking a significant decline amid ongoing market pressures and sector underperformance. The stock’s recent performance highlights persistent challenges reflected in its valuation and financial metrics.
Read full news article
Choksi Laboratories Ltd is Rated Strong Sell
2026-03-04 10:10:55Choksi Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read full news article
Choksi Laboratories Downgraded to Strong Sell Amid Technical and Fundamental Weakness
2026-02-18 08:03:51Choksi Laboratories Ltd, a key player in the Healthcare Services sector, has seen its investment rating downgraded from Sell to Strong Sell as of 17 Feb 2026. This shift reflects deteriorating technical indicators, stagnant financial performance, and a challenging valuation backdrop, signalling caution for investors amid underwhelming market returns and weak fundamental metrics.
Read full news article
Choksi Laboratories Ltd Upgraded to Sell on Flat Financials and Mixed Technicals
2026-02-13 08:03:42Choksi Laboratories Ltd, a healthcare services company, has seen its investment rating downgraded from Strong Sell to Sell following a reassessment of its financial performance, valuation, technical indicators, and overall quality metrics. The downgrade reflects a cautious stance amid flat quarterly results, subdued financial trends, and mixed technical signals, despite some attractive valuation parameters.
Read full news article
Choksi Laboratories Ltd is Rated Strong Sell
2026-02-10 10:11:11Choksi Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 07 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.
Read full news articleAre Choksi Laboratories Ltd latest results good or bad?
2026-02-07 19:17:55Choksi Laboratories Ltd reported its financial results for the quarter ending December 2025, reflecting a mixed operational performance. The company achieved a net profit of ₹0.31 crores, which represents a significant year-on-year growth of 181.82%. This growth is notable, especially when compared to the previous year's performance. However, the revenue for the same period amounted to ₹10.82 crores, indicating a modest year-on-year increase of 4.24%, which is a decline from the previous year's growth rate of 18.09%. The operating margin for Choksi Laboratories stood at 24.31%, showing a compression of 204 basis points from the previous quarter, which raises concerns about operational efficiency. Additionally, the company faced an unusually high tax rate of 65.56%, which has impacted the net profit margin, leaving it at a mere 2.87%. This high tax rate may suggest potential issues with earnings quality or ...
Read full news article
Choksi Laboratories Q3 FY26: Profit Surge Masked by Margin Compression and Tax Anomalies
2026-02-07 17:46:55Choksi Laboratories Ltd., a micro-cap contract testing and analytical services provider with a market capitalisation of ₹85.00 crores, reported a net profit of ₹0.31 crores for Q3 FY26 (October-December 2025), representing a sequential increase of 29.17% quarter-on-quarter but a substantial 181.82% surge year-on-year from ₹0.11 crores in Q3 FY25. However, the headline profit growth conceals troubling underlying trends, including persistent margin compression, an extraordinarily high tax rate of 65.56%, and declining operating efficiency that raise serious questions about the sustainability of this performance.
Read full news articleAnnouncement under Regulation 30 (LODR)-Newspaper Publication
09-Feb-2026 | Source : BSESubmission of published unaudited financial result for the quarter and nine month ended 31.12.2025 in the newspaper
Financial Result For The Quarter And Nine Month Ended 31.12.2025
07-Feb-2026 | Source : BSEConsidered and approved quarterly financial result for the period ended 31.12.2025
Intimation Of Re-Constitution Of Various Committees Of Board Of Directors Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015
07-Feb-2026 | Source : BSEIntimation of Reconstitution of committees of board of directors
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available






